EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants

Shabir A Madhi, Eric A F Simões iD, Armando Acevedo iD, Jose M Novoa Pizarro, Julie S Shepard, Radha A Railkar, Xin Cao, Brian M Maas iD, Xiaowei Zang iD, Andrea Krick, Brad Roadcap, Kalpit A Vora iD und 3 weitere

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiae581 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Shabir A Madhi und 14 weiteren Autor:innen. Beteiligte Einrichtung: South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwat…. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Antibodies, Neutralizing, Antibodies, Monoclonal, Humanized, Antibodies, Viral. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Merck Sharp & Dohme LLC, Merck & Co, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clesrovimab is an investigational monoclonal antibody with an extended half-life targeting site IV of the respiratory syncytial virus (RSV) fusion protein for the prevention of RSV disease in infants.

Methods

In this phase 1b/2a, double-blind study, 183 healthy preterm and full-term infants 2 weeks to 8 months of age were randomized 4:1 within 5 panels (preterm 20, 50, 75, or 100 mg; full-term 100 mg) to receive 1 dose of clesrovimab or placebo. The objectives were to evaluate safety, pharmacokinetics, serum neutralizing antibodies (SNA), and antidrug antibodies (ADA). The incidence of RSV-associated end points (medically attended lower respiratory tract infection, hospitalization, and acute respiratory infection) were also evaluated through 150 days postdose.

Results

The most common adverse event through day 14 was irritability; no treatment-related serious AEs were reported. Clesrovimab serum concentrations displayed a geometric mean apparent half-life of 44.9 days. Of participants receiving clesrovimab, 51 (36.7%) developed ADA with no apparent impact in pharmacokinetics. SNA titers increased in a dose-dependent manner at day 150. The incidences of RSV-associated end points were lower in infants treated with clesrovimab compared with placebo.

Conclusions

Clesrovimab was generally well tolerated and exhibited an extended half-life compared to typical IgG1 antibodies, supporting its ongoing development in late-stage trials. Clinical Trial Registration. NCT03524118.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsAntibodies, NeutralizingAntibodies, Monoclonal, HumanizedAntibodies, ViralRespiratory Syncytial Virus, HumanAntiviral AgentsAntibodies, MonoclonalHumansDouble-Blind MethodMaleFemaleHalf-LifeInfantInfant, PrematureInfant, Newborn

Stichwörter der Autor:innen

RSVclesrovimabmonoclonal antibody

Substanzen

Antibodies, NeutralizingAntibodies, Monoclonal, HumanizedAntibodies, ViralAntiviral AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa.
  • Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Colorado School of Public Health, Aurora, Colorado, USA.
  • Acevedo Clinical Research Associates, Miami, Florida, USA.
  • Hospital Padre Alberto Hurtado, Santiago, Chile.
  • Ohio Pediatric Research Association, Dayton, Ohio, USA.

ORCID-Profile: Eric A F Simões, Armando Acevedo, Brian M Maas, Xiaowei Zang, Kalpit A Vora

Förderung

  • Merck Sharp & Dohme LLC
  • Merck & Co, Inc

Zitieren

APA

Madhi, S. A., Simões, E. A. F., Acevedo, A., Novoa Pizarro, J. M., Shepard, J. S., Railkar, R. A., Cao, X., Maas, B. M., Zang, X., Krick, A., Roadcap, B., Vora, K. A., Aliprantis, A. O., Lee, A. W., & Sinha, A. (2025). A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae581

Vancouver

Madhi SA, Simões EAF, Acevedo A, Novoa Pizarro JM, Shepard JS, Railkar RA, et al. A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae581

BibTeX
@article{Madhi2025,
  author = {Madhi, Shabir A and Simões, Eric A F and Acevedo, Armando and Novoa Pizarro, Jose M and Shepard, Julie S and Railkar, Radha A and Cao, Xin and Maas, Brian M and Zang, Xiaowei and Krick, Andrea and Roadcap, Brad and Vora, Kalpit A and Aliprantis, Antonios O and Lee, Andrew W and Sinha, Anushua},
  title = {A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiae581}
}
Kostenlos starten →